Guest guest Posted November 28, 2007 Report Share Posted November 28, 2007 This was posted by a friend who knew that I was taking SAM-e. I'm including the whole bulletin because there are other items of interest. Penny You are receiving this email from American Liver Foundation because you have expressed interest and support for our work. To ensure that you continue to receive emails from us, add lneier@... to your address book today. If you haven't done so already, click to confirm http://visitor.constantcontact.com/c.jsp?t=1101887101041.11729.441023105.2 & m=110\ 1326596412 & wl=F your interest in receiving email campaigns from us. You may unsubscribe http://visitor.constantcontact.com/d.jsp?p=un & v=001SJ0VA3zU47lbBVzh4-0vwEI-nCdNS\ kKOF6RerSPlabbp0t3xKOoYSFuYd89mvZxHuLzH9bv4muVLoOvog3ifyg%3D%3D if you no longer wish to receive our emails. ------------------------------------------------------------ 2007 The Monday Update American Liver Foundation Newsletter Greetings! This newsletter aims to keep you up to date with the latest developments in the areas of liver medicine and science. Here are the top liver news stories for the past week. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ FDA Approves Nexavar For Liver Cancer Therapy The US Food and Drug Administration (FDA) has approved Nexavar (sorafenib) tablets, a supplemental NDA (new drug application) for patients with liver cancer. It is the first approved systemic drug therapy for liver cancer, as well as being the only medication therapy proven to significantly improve overall survival in liver cancer patients. L. Boyer, M.D., Chairman, American Liver Foundation, said " The American Liver Foundation (ALF) is always pleased when new therapies prove effective for those affected by liver disease. Researchers worldwide, including those supported by ALF, have spent decades studying liver cancer. This new treatment provides a valuable option for liver cancer patients and will enable ALF to further promote the treatment of liver disease through our education and advocacy efforts. " * Medical News Today - http://rs6.net/tn.jsp?e=001KwTkTmzNaaT3agE2uAWprV6plQSBra48apRN1oLAXrRJ1WaUogQz3\ FfytfZKPFzJ7jcQlMDKPqlRsXLQaw2BGC0h2khAE9Gwg149PN4YO13E1e1xcLxnW7nkpAyV0CrmtXxPl\ JmThxT3ApBx35eI3g== ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ New Organ Allocation Criteria Associated With Decreased Deaths On Liver Transplant Waiting List Changing the method by which donated livers are allocated to potential transplant patients appears to have decreased the number of deaths among individuals on the waiting list as well as shortened the time to transplantation, according to a report in the Archives of Surgery. * Science Daily - http://rs6.net/tn.jsp?e=001KwTkTmzNaaQOc5gqm3ulhlJIbMX-DSZuxFnot0rXf1bkg_HCOG9xO\ T3_tu3Lhld7YA41fVqN-Zrj9iSO13JXkXbVO9kwBMdTj4DNCarIaFZJHS8AD8VVnYLsOOtqfcurv2ESv\ 9WRWCVKxY-2MfxA6ltCscrPeFhgfffUK_FnedE= ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Arthritis drug withdrawn over liver damage fears The license for Prexige, an arthritis drug that has been avaiable in the UK since 2005, has been suspended amid concerns that it may cause liver damage. Brittish regulators ordered Prexige to be withdrawn from the market immediately. The drug was used to treat painful symptoms of osteoarthritis of the knee and hip The drug was used to treat painful symptoms of osteoarthritis of the knee and hip. There have been 23 reports of suspected adverse reactions to lumiracoxib in the UK since March 2006, three of which related to liver problems, although none of the reactions were said to have been severe. * Daily Mail - http://rs6.net/tn.jsp?e=001KwTkTmzNaaQ9972AzPa5MFiu9EHl0Qk5E-iOPwJOF5_jw08Lp6K0s\ 5KmpaOj-PVa_-xJl8b7bysEH96QLt3fpAaUOpmtCMnHgBfVSqrKZcR8QicyAOioe0cHeHhuitta2IAAU\ 4wqMRAJoY8yDG27-wX12bGTT0J-bjd6-cXYzTeQbypcTReGxLFTTCzlM6xfoAxMIjlelpv2dFCKZoWiW\ SUBeJYhCbhWlOZdRg-CI5fv6DlTc__5YknfCYuoLffxzOLXvbhY2Ck= ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ SAMe and Liver Disease Study Shows Supplement May be Help Alcoholics The supplement SAMe which proved disappointing as a treatment for arthritis and depression as it was originally promoted, may now offer some hope for those who suffer from chronic liver disease. A study by the Univerisity of California in 1999 researched how SAMe worked for alcoholics. The study published in the Journal of Hepatology showed that a group of alcoholics who received SAMe had a 30 percent reduction in deaths and liver transplants, compared with a group of patients who did not receive the supplement. .. Research has shown that patients with alcoholic liver disease and other liver disorders have abnormal methionine metabolism, which depletes SAMe. Taking therapeutic doses of SAMe helps reverse that affect * About.com: Alcohol - http://rs6.net/tn.jsp?e=001KwTkTmzNaaS15z1EjWwGtkb6r3nUcD3iTCyzO3hH0rY-W9GhvwTHj\ Y2FQzh786AkZFrPAcfJqYAf73esaIkN7alFDJJYpIaf2_1puZOmSZyiZ-Qy_N6cbxjxUZOqIjxFKMlxn\ puTstdY7CiQrs-6RvxiOX-mWQt8 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ email: lneier@... phone: web: http://www.liverfoundation.org ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Thank you for your continued support of the American Liver Foundation. For more information on liver disease or our work as an organization, please visit our website or contact your local ALF chapter. Forward email http://ui.constantcontact.com/sa/fwtf.jsp?m=1101326596412 & ea=iwryte2%40aol.com & a\ =1101887101041 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.